Investigator

Philip D. Dunne

Queen's University Belfast

PDDPhilip D. Dunne
Papers(1)
Biological Misinterpr…
Collaborators(10)
Raheleh AmirkhahRyan M. ByrneSimon LeedhamSudhir B. MallaTim MaughanViktor H. KoelzerAndrew J. CameronBaharak AhmaderaghiEnric DomingoFelicity Lamrock
Institutions(4)
Queens University Bel…Centre for Human Gene…Universität ZürichUniversity of Glasgow

Papers

Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data

Abstract Purpose: Precise mechanism-based gene expression signatures (GES) have been developed in appropriate in vitro and in vivo model systems, to identify important cancer-related signaling processes. However, some GESs originally developed to represent specific disease processes, primarily with an epithelial cell focus, are being applied to heterogeneous tumor samples where the expression of the genes in the signature may no longer be epithelial-specific. Therefore, unknowingly, even small changes in tumor stroma percentage can directly influence GESs, undermining the intended mechanistic signaling. Experimental Design: Using colorectal cancer as an exemplar, we deployed numerous orthogonal profiling methodologies, including laser capture microdissection, flow cytometry, bulk and multiregional biopsy clinical samples, single-cell RNA sequencing and finally spatial transcriptomics, to perform a comprehensive assessment of the potential for the most widely used GESs to be influenced, or confounded, by stromal content in tumor tissue. To complement this work, we generated a freely-available resource, ConfoundR; https://confoundr.qub.ac.uk/, that enables users to test the extent of stromal influence on an unlimited number of the genes/signatures simultaneously across colorectal, breast, pancreatic, ovarian and prostate cancer datasets. Results: Findings presented here demonstrate the clear potential for misinterpretation of the meaning of GESs, due to widespread stromal influences, which in-turn can undermine faithful alignment between clinical samples and preclinical data/models, particularly cell lines and organoids, or tumor models not fully recapitulating the stromal and immune microenvironment. Conclusions: Efforts to faithfully align preclinical models of disease using phenotypically-designed GESs must ensure that the signatures themselves remain representative of the same biology when applied to clinical samples.

146Works
1Papers
14Collaborators

Positions

Researcher

Queen's University Belfast

2022–

Reader in Molecular Pathology and Early Detection

Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences · Patrick G Johnston Centre for Cancer Research

2022–

Group Leader

Cancer Research UK Beatson Institute

2016–

Senior Research Fellow

Queens University Belfast · School of Medicine

Education

2010

PhD

University Of Ulster School of Biomedical Sciences · Stem cell development and epigenetics